Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Overview of attention for article published in Lancet Oncology, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 29 news outlets
blogs: 4 blogs
policy: 3 policy sources
twitter: 36 X users

patent: 22 patents
f1000: 1 research highlight platform
guideline: 10 clinical guideline sources

Readers on

mendeley: 1358 Mendeley

So far, Altmetric has seen 47 news stories from 29 outlets.

Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma

Cancer Network, 08 Feb 2024

In 2023, the Lymphoma Research Foundation hosted the Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss…

The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease

Cancer Network, 21 Dec 2022

ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

OncLive, 20 Aug 2022

In Partnership With: In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have…

Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas

Cancer Network, 18 Aug 2022

P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 43 additional news stories.